Non-response to citalopram in depressive patients: Pharmacokinetic and clinical consequences of a fluvoxamine augmentation

Psychopharmacology

Volumn 128, Issue 4, 1996, Pages 421-425

  Bondolfi, G ^a,b   Chautems, C ^a   Rochat, B ^a   Bertschy, G ^a   Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b Hopital de Cery   (Switzerland)

Author keywords

citalopram; depression; fluvoxamine; pharmacokinetic interaction

Indexed keywords

CITALOPRAM; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DRUG METABOLITE; FLUVOXAMINE; MEPHENYTOIN;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; ENANTIOMER; FEMALE; HEADACHE; HUMAN; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; STEREOSPECIFICITY; TREMOR;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HUMANS; MIDDLE AGED; NAUSEA; SEROTONIN UPTAKE INHIBITORS; TREMOR;

EID: 0029903801     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050152     Document Type: Article

References (31)

1. Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8:238-249
2. Baumann P, Larsen F (1995) The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287-295
3. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B (1992) Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 14:1-8
4. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M (1996) A double-blind placebo controlled study of citalopram with and without lithium in the treatment of therapy-resistent depressive patients. J Clin Psychopharmacol 16:307-314
5. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol 40:119-120
6. Brøsen K (1996) Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 11 [suppl. 1]:23-27
7. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214
8. Brown WA, Harrison W (1995) Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 56:30-34
9. Conus P, Bondolfi G, Eap CB, Macciardi F, Baumann P (1996) Pharmacokinetic fluvoxamine-clomipramine interaction with favourable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry 29:108-110
10. Covi L, Lipman LS (1984) Primary depression or primary anxiety? A possible psychometric approach to a diagnostic dilemma. Clin Neuropharmacol 7 [Suppl. 1] 924-925
11. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265
12. Eap CB, Gaillard N, Powell K, Baumann P (1996) Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography - mass spectrometry. J Chromatogr B: Biomed Appl (in press)
13. Hantouche EG, Chignon JM, Adès J (1992) Echelle de dyscontrôle comportemental. Validation et résultats préliminaires. Encéphale XVIII:163-170
14. Hyttel J, Bøgesø KP, Perregaard J, Sanchez C (1992) The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. Short communication. J Neural Transm Gen Sect 88: 157-160
15. Hyttel J, Arnt J, Sanchez C (1995) The pharmacology of citalopram. Rev Contemp Pharmacother 6:271-285
16. Kasper S, Höflich G, Scholl H-P, Möller H-J (1994) Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 9:1-12
17. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM (1995) The emerging role of cytochrome P4503A in psychopharmacology. J Clin Psychopharmacol 15:387-398
18. Lejoyeux M, Adès J, Rouillon F (1994) Serotonin syndrome - incidence, symptoms and treatment. CNS Drugs 2:132-143
19. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 334:81-94
20. Möller H-J (1994) Non-response to antidepressants: risk factors and therapeutic possibilities. Int Clin Psychopharmacol 9 [suppl. 2]: 17-23
21. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
22. Montgomery SA, Pedersen V, Tanghøj P, Rasmussen C, Rioux P (1994) The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 9 [suppl. 1]: 35-40
23. Rihs M, Müller C, Baumann P (1996) Caffeine consumption in hospitalized psychiatric patients. Eur Arch Psychiatry Clin Neurosci 246:83-92
24. Rochat B, Amey M, Baumann P (1995a) Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 17:273-279
25. Rochat B, Amey M, van Gelderen H, Testa B, Baumann P (1995b) Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 7:389-395
26. Rochat B, Amey M, Baumann P (1996) Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics (in press)
27. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Fredricson Overø K, Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:1-17
28. Skjelbo E, Brøsen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34:256 261
29. Sokolov STH, Joffe RT (1995) Practical guidelines for combination drug therapy of treatment-resistant depression. CNS Drugs 4:341-350
30. Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705-713
31. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, François T, Sechter D, Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine, and neuroleptics in phenotyped patients. Pharmacol Res 31:347-353